title: Evidence for an intranasal immune response to human respiratory syncytial virus infection in cynomolgus macaques.
abstract: There is no large-scale therapy available against human respiratory syncytial virus (hRSV), a major pathogen responsible for acute respiratory diseases. Macaques represent an interesting animal model to evaluate potential treatments because of their genetic, anatomical and immunological proximity with humans. However, the parameters that influence hRSV growth and control in this model are still poorly understood. We have documented in the following study the influence of age as well as repeated infections on the virological, clinical and immunological parameters of this animal model. Following intranasal inoculation, hRSV replicated in the upper respiratory tract for less than 15 days with no clinical signs regardless of age. Interestingly, we observed the induction of a local immune response at the nasal mucosa as assessed by expression profiles of inflammatory and IFN-stimulated genes. Animals also developed specific antibodies and were immune to reinfection. Thus, we showed that even in infant macaques, intranasal hRSV infection induced both local and systemic immune responses to efficiently control the virus.
authors.affiliation: CNRS, UMR3569, Paris, France.|Institut Pasteur, Unité de Génomique Virale et Vaccination, Paris, France.|Cynbiose SA, Marcy-l'Etoile, France.
authors.forename: Clément
authors.initials: C
authors.lastname: Grandin
authors.affiliation: CNRS, UMR3569, Paris, France.|Institut Pasteur, Unité de Génomique Virale et Vaccination, Paris, France.
authors.forename: Marianne
authors.initials: M
authors.lastname: Lucas-Hourani
authors.affiliation: Cynbiose SA, Marcy-l'Etoile, France.
authors.forename: Marine
authors.initials: M
authors.lastname: Clavel
authors.affiliation: Cynbiose SA, Marcy-l'Etoile, France.
authors.forename: Fabrice
authors.initials: F
authors.lastname: Taborik
authors.affiliation: Université de Caen-Basse-Normandie, EA 4655-U2RM, Laboratoire de Virologie, CHU de Caen, France.
authors.forename: Astrid
authors.initials: A
authors.lastname: Vabret
authors.affiliation: CNRS, UMR3569, Paris, France.|Institut Pasteur, Unité de Génomique Virale et Vaccination, Paris, France.
authors.forename: Frédéric
authors.initials: F
authors.lastname: Tangy
authors.affiliation: Cynbiose SA, Marcy-l'Etoile, France.
authors.forename: Hugues
authors.initials: H
authors.lastname: Contamin
authors.affiliation: CNRS, UMR3569, Paris, France.|Institut Pasteur, Unité de Génomique Virale et Vaccination, Paris, France.
authors.forename: Pierre-Olivier
authors.initials: PO
authors.lastname: Vidalain
mesh_terms: D000281:Administration, Intranasal / Q000379:methods; D000367:Age Factors; D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology; D002460:Cell Line; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D007372:Interferons / Q000276:immunology; D008252:Macaca fascicularis / Q000276:immunology* / Q000821:virology; D008297:Male; D009297:Nasal Mucosa / Q000276:immunology* / Q000821:virology; D011247:Pregnancy; D018357:Respiratory Syncytial Virus Infections / Q000276:immunology* / Q000821:virology; D018113:Respiratory Syncytial Virus, Human / Q000276:immunology*; D012141:Respiratory Tract Infections / Q000276:immunology* / Q000821:virology; D014779:Virus Replication / Q000276:immunology
chemical_list: D000914:Antibodies, Viral; D007372:Interferons